{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:23:11Z","timestamp":1762899791683},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:00:00Z","timestamp":1565740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:00:00Z","timestamp":1565740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C8162\/A16892","C8162\/A16892"],"award-info":[{"award-number":["C8162\/A16892","C8162\/A16892"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Partly funded through Public Health England."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2019,9,10]]},"DOI":"10.1038\/s41416-019-0547-x","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T23:04:10Z","timestamp":1565737450000},"page":"455-463","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["16\/18 genotyping in triage of persistent human papillomavirus infections with negative cytology in the English cervical screening pilot"],"prefix":"10.1038","volume":"121","author":[{"name":"on behalf of HPV Pilot Steering Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matejka","family":"Rebolj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam R.","family":"Brentnall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Denton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miles","family":"Holbrook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Sargent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Tidy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xenia","family":"Tyler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Kitchener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,14]]},"reference":[{"key":"547_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/cyt.12236","volume":"26","author":"HC Kitchener","year":"2015","unstructured":"Kitchener, H. C. HPV primary cervical screening: time for a change. Cytopathology 26, 4\u20136 (2015).","journal-title":"Cytopathology"},{"key":"547_CR2","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ygyno.2014.12.022","volume":"136","author":"WK Huh","year":"2015","unstructured":"Huh, W. K., Ault, K. A., Chelmow, D., Davey, D. D., Goulart, R. A., Garcia, F. A. et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol. Oncol. 136, 178\u2013182 (2015).","journal-title":"Gynecol. Oncol."},{"key":"547_CR3","unstructured":"Australian Government (Department of Health). Changes to the National Cervical Screening Program (NCSP) for Healthcare Providers From 1 December 2017. \n                    http:\/\/www.cancerscreening.gov.au\/internet\/screening\/publishing.nsf\/Content\/1-december-changes-fact-sheet\n                    \n                   (2018)."},{"key":"547_CR4","doi-asserted-by":"publisher","first-page":"8813","DOI":"10.1158\/0008-5472.CAN-08-1380","volume":"68","author":"MT Goodman","year":"2008","unstructured":"Goodman, M. T., Shvetsov, Y. B., McDuffie, K., Wilkens, L. R., Zhu, X., Thompson, P. J. et al. Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. Cancer Res. 68, 8813\u20138824 (2008).","journal-title":"Cancer Res."},{"key":"547_CR5","doi-asserted-by":"publisher","first-page":"e79260","DOI":"10.1371\/journal.pone.0079260","volume":"8","author":"U Jaisamrarn","year":"2013","unstructured":"Jaisamrarn, U., Castellsague, X., Garland, S. M., Naud, P., Palmroth, J., Del Rosario-Raymundo, M. R. et al. Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study. PLoS ONE 8, e79260 (2013).","journal-title":"PLoS ONE"},{"key":"547_CR6","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/ijc.27986","volume":"133","author":"CE Schmeink","year":"2013","unstructured":"Schmeink, C. E., Massuger, L. F., Lenselink, C. H., Quint, W. G., Witte, B. I., Berkhof, J. et al. Prospective follow-up of 2,065 young unscreened women to study human papillomavirus incidence and clearance. Int. J. Cancer 133, 172\u2013181 (2013).","journal-title":"Int. J. Cancer"},{"key":"547_CR7","doi-asserted-by":"publisher","first-page":"l240","DOI":"10.1136\/bmj.l240","volume":"364","author":"M Rebolj","year":"2019","unstructured":"Rebolj, M., Rimmer, J., Denton, K., Tidy, J., Mathews, C., Ellis, K. et al. Primary cervical screening with high risk human papillomavirus testing: observational study. BMJ 364, l240 (2019).","journal-title":"BMJ"},{"key":"547_CR8","doi-asserted-by":"publisher","first-page":"e0147326","DOI":"10.1371\/journal.pone.0147326","volume":"11","author":"M Rebolj","year":"2016","unstructured":"Rebolj, M., Bonde, J., Preisler, S., Ejegod, D., Rygaard, C. & Lynge, E. Human papillomavirus assays and cytology in primary cervical screening of women aged 30 years and above. PLoS ONE 11, e0147326 (2016).","journal-title":"PLoS One"},{"key":"547_CR9","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1128\/JCM.01013-15","volume":"53","author":"T Iftner","year":"2015","unstructured":"Iftner, T., Becker, S., Neis, K. J., Castanon, A., Iftner, A., Holz, B. et al. Head-to-head comparison of the RNA-based aptima human papillomavirus (HPV) assay and the DNA-based hybrid capture 2 HPV test in a routine screening population of women aged 30 to 60 years in Germany. J. Clin. Microbiol. 53, 2509\u20132516 (2015).","journal-title":"J. Clin. Microbiol."},{"key":"547_CR10","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1309\/PT3PNC1QL2F4D2VL","volume":"127","author":"PE Castle","year":"2007","unstructured":"Castle, P. E., Stoler, M. H., Solomon, D. & Schiffman, M. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. Am. J. Clin. Pathol. 127, 805\u2013815 (2007).","journal-title":"Am. J. Clin. Pathol."},{"key":"547_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ygyno.2014.11.076","volume":"136","author":"TC Wright","year":"2015","unstructured":"Wright, T. C., Stoler, M. H., Behrens, C. M., Sharma, A., Zhang, G. & Wright, T. L. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol. Oncol. 136, 189\u2013197 (2015).","journal-title":"Gynecol. Oncol."},{"key":"547_CR12","unstructured":"R. Core Team. R: A language and environment for statistical computing. \n                    https:\/\/www.R-project.org\n                    \n                   (2017)."},{"key":"547_CR13","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1093\/jnci\/dji159","volume":"97","author":"S Franceschi","year":"2005","unstructured":"Franceschi, S. & Clifford, G. M. Re: A study of the impact of adding HPV types to cervical cancer screening and triage tests. J. Natl Cancer Inst. 97, 938\u2013939 (2005).","journal-title":"J. Natl Cancer Inst."},{"key":"547_CR14","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/jnci\/dji187","volume":"97","author":"MJ Khan","year":"2005","unstructured":"Khan, M. J., Castle, P. E., Lorincz, A. T., Wacholder, S., Sherman, M., Scott, D. R. et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl Cancer Inst. 97, 1072\u20131079 (2005).","journal-title":"J. Natl Cancer Inst."},{"key":"547_CR15","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1093\/jnci\/djq356","volume":"102","author":"SK Kjaer","year":"2010","unstructured":"Kjaer, S. K., Frederiksen, K., Munk, C. & Iftner, T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J. Natl Cancer Inst. 102, 1478\u20131488 (2010).","journal-title":"J. Natl Cancer Inst."},{"key":"547_CR16","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/bjc.1991.350","volume":"64","author":"GJ van Oortmarssen","year":"1991","unstructured":"van Oortmarssen, G. J. & Habbema, J. D. Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. Br. J. Cancer 64, 559\u2013565 (1991).","journal-title":"Br. J. Cancer"},{"key":"547_CR17","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/S1470-2045(08)70110-4","volume":"9","author":"M Schiffman","year":"2008","unstructured":"Schiffman, M. & Rodriguez, A. C. Heterogeneity in CIN3 diagnosis. Lancet Oncol. 9, 404\u2013406 (2008).","journal-title":"Lancet Oncol."},{"key":"547_CR18","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1038\/sj.bjc.6601355","volume":"89","author":"MarieME van den Akker-van","year":"2003","unstructured":"van den Akker-van, Marie M. E., van Ballegooijen, M., Rozendaal, L., Meijer, C. J. & Habbema., J. D. Extended duration of the detectable stage by adding HPV test in cervical cancer screening. Br. J. Cancer 89, 1830\u20131833 (2003).","journal-title":"Br. J. Cancer"},{"key":"547_CR19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(08)70103-7","volume":"9","author":"MR McCredie","year":"2008","unstructured":"McCredie, M. R., Sharples, K. J., Paul, C., Baranyai, J., Medley, G., Jones, R. W. et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 9, 425\u2013434 (2008).","journal-title":"Lancet Oncol."},{"key":"547_CR20","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1309\/AJCPTGD94EVRSJCG","volume":"137","author":"D Saslow","year":"2012","unstructured":"Saslow, D., Solomon, D., Lawson, H. W., Killackey, M., Kulasingam, S. L., Cain, J. et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am. J. Clin. Pathol. 137, 516\u2013542 (2012).","journal-title":"Am. J. Clin. Pathol."},{"key":"547_CR21","unstructured":"European Commission. European guidelines for quality assurance in cervical cancer screening. 2nd edn\u2014Supplements. \n                    http:\/\/bookshop.europa.eu\/en\/european-guidelines-for-quality-assurance-in-cervical-cancer-screening-pbEW0115451\/?AllPersonalAuthorNames=true\n                    \n                   (2015)."},{"key":"547_CR22","unstructured":"National Institute for Public Health and the Environment. Uitslagen uitstrijkje. URL: \n                    https:\/\/www.rivm.nl\/Onderwerpen\/B\/Bevolkingsonderzoek_baarmoederhalskanker\/Uitslag_bevolkingsonderzoek\/Uitslagen_uitstrijkje\n                    \n                   (2018)."},{"key":"547_CR23","first-page":"77","volume":"39","author":"G Ronco","year":"2015","unstructured":"Ronco, G., Giorgi Rossi, P., Giubilato, P., Del Mistro, A., Zappa, M. & Carozzi, F., group HPVss. A first survey of HPV-based screening in routine cervical cancer screening in Italy. Epidemiol. Prev. 39, 77\u201383 (2015).","journal-title":"Epidemiol. Prev."},{"key":"547_CR24","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S1473-3099(17)30468-1","volume":"17","author":"K Kavanagh","year":"2017","unstructured":"Kavanagh, K., Pollock, K. G., Cuschieri, K., Palmer, T., Cameron, R. L., Watt, C. et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect. Dis. 17, 1293\u20131302 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"547_CR25","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1002\/ijc.30030","volume":"138","author":"R Bhatia","year":"2016","unstructured":"Bhatia, R., Kavanagh, K., Cubie, H. A., Serrano, I., Wennington, H., Hopkins, M. et al. Use of HPV testing for cervical screening in vaccinated women\u2013Insights from the SHEVa (Scottish HPV Prevalence in Vaccinated Women) study. Int. J. Cancer 138, 2922\u20132931 (2016).","journal-title":"Int. J. Cancer"},{"key":"547_CR26","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.jval.2015.09.2939","volume":"18","author":"JF O\u2019Mahony","year":"2015","unstructured":"O\u2019Mahony, J. F., Naber, S. K., Normand, C., Sharp, L., O\u2019Leary, J. J. & de Kok, I. M. Beware of Kinked Frontiers: a systematic review of the choice of comparator strategies in cost-effectiveness analyses of human papillomavirus testing in cervical screening. Value Health 18, 1138\u20131151 (2015).","journal-title":"Value Health"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0547-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0547-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0547-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:05:32Z","timestamp":1684616732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-019-0547-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,14]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,9,10]]}},"alternative-id":["547"],"URL":"https:\/\/doi.org\/10.1038\/s41416-019-0547-x","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"type":"print","value":"0007-0920"},{"type":"electronic","value":"1532-1827"}],"subject":[],"published":{"date-parts":[[2019,8,14]]},"assertion":[{"value":"16 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.R.: PHE provided financing for the epidemiological evaluation; attended meetings with various HPV assay manufacturers; fee for lecture from Hologic paid to employer. C.M.: Partly funded by PHE that provided financing for the epidemiological evaluation. K.D. has received speaker fees and travel expenses to attend meetings from Hologic. M.H., T.L., X.T.: PHE provided funding to support the NHS screening laboratory activity for the pilot. A.S.: Attended meetings with HPV assay manufacturers; speaker fees from Roche; travel and accommodation from Roche for training and from Abbott for user group meeting; Roche, Abbott, Hologic, Becton Dickinson and Cepheid provided kits for assay validation purposes; PHE provided funding to support the NHS screening laboratory activity for the pilot. J.S.: Personal speaker bureau fees from Beckton Dickinson; personal medical advisory board fees from Zilico. J.T.: Fees for lectures from Roche, Qiagen and Hologic; conference registration, accommodation and travel from Sanofi Pasteur; consultancy fees and shareholder in Zilico; patent for electrical impedance spectroscopy in detection of cervical intraepithelial neoplasia with Zilico. H.K.: Chair of the Advisory Committee for Cervical Screening (PHE), but the views expressed in this manuscript are those of the author and do not represent the view of PHE. A.R.B. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Women participating in the HPV primary screening pilot were invited to make an informed choice on participating in the cervical screening programme. A decision is made to accept or decline a screening test based on access to accurate and up-to-date information on the condition being screened for, the testing process and potential outcomes. Specific information was provided at the invitation stage allowing for personalised informed choice. There was further opportunity to reflect on what the test and its results might mean when they attended for screening with the clinician taking the sample. Regulation 5, Health Service Regulations 2002, Confidentiality Advisory Group Reference: 15\/CAG\/0207, was the legal basis to process the data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The funding for the pilot and the epidemiological evaluation thereof was provided by PHE. PHE had a role in designing the pilot; in the collection of the data; and commented on the manuscript. M.R. and H.K. made the final decision to submit. M.R. and (partly) C.M. were funded through Cancer Research UK, grant number C8162\/A16892. A.R.B. was funded through Cancer Research UK, grant number C569\/A16891.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"No additional unpublished data are available from the authors. Requests for access to data should be made to Public Health England, Office for Data Release.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}